Potential application of [18F]AlF-PSMA-11 PET/CT in radioiodine refractory thyroid carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Potential application of [18F]AlF-PSMA-11 PET/CT in radioiodine refractory thyroid carcinoma ; volume:14 ; number:1 ; day:12 ; month:9 ; year:2024 ; pages:1-10 ; date:12.2024
EJNMMI Research ; 14, Heft 1 (12.9.2024), 1-10, 12.2024
- Classification
-
Medizin, Gesundheit
- Creator
-
Van den Broeck, Bliede
Debacker, Jens M.
Bauters, Wouter
Creytens, David
Ferdinande, Liesbeth
Huvenne, Wouter
Lapauw, Bruno
Schelfhout, Vanessa
Van Laeken, Nick
Verroken, Charlotte
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13550-024-01148-9
- URN
-
urn:nbn:de:101:1-2411262100219.322897835575
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Van den Broeck, Bliede
- Debacker, Jens M.
- Bauters, Wouter
- Creytens, David
- Ferdinande, Liesbeth
- Huvenne, Wouter
- Lapauw, Bruno
- Schelfhout, Vanessa
- Van Laeken, Nick
- Verroken, Charlotte
- SpringerLink (Online service)
Other Objects (12)
![Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007](/assets/placeholder/searchResultMediaUnknown.png)
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Pitfalls in PSMA imaging: [18F]rhPSMA-7-PET/CT reveals presence of chrondrosarcoma
Clinico-pathological factors and [18F]FDG PET/CT metabolic parameters for prediction of progression-free survival in radioiodine refractory differentiated thyroid carcinoma
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Clinical experience with 18F-JK-PSMA-7 when using a digital PET/CT
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
Heterogeneous uptake of 18F-FDG and 18F-PSMA-1007 PET/CT in lung cancer and lymph node metastasis
PSMA-Liganden PET/CT bei Patienten mit biochemischem Rezidiv nach radikaler Prostatektomie: Matched-Pair Vergleich von 68Ga-PSMA-11 und 18F-PSMA-1007
Progressive Unilateral Proptosis and (18F) FDG-Avid Lesions Connoting Aggressive Disease in Radioiodine-Refractory Differentiated Thyroid Carcinoma
[18F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Pitfalls in PSMA imaging: [18F]rhPSMA-7-PET/CT reveals presence of chrondrosarcoma
Clinico-pathological factors and [18F]FDG PET/CT metabolic parameters for prediction of progression-free survival in radioiodine refractory differentiated thyroid carcinoma
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Clinical experience with 18F-JK-PSMA-7 when using a digital PET/CT
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
Heterogeneous uptake of 18F-FDG and 18F-PSMA-1007 PET/CT in lung cancer and lymph node metastasis
PSMA-Liganden PET/CT bei Patienten mit biochemischem Rezidiv nach radikaler Prostatektomie: Matched-Pair Vergleich von 68Ga-PSMA-11 und 18F-PSMA-1007
Progressive Unilateral Proptosis and (18F) FDG-Avid Lesions Connoting Aggressive Disease in Radioiodine-Refractory Differentiated Thyroid Carcinoma
[18F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Pitfalls in PSMA imaging: [18F]rhPSMA-7-PET/CT reveals presence of chrondrosarcoma
Clinico-pathological factors and [18F]FDG PET/CT metabolic parameters for prediction of progression-free survival in radioiodine refractory differentiated thyroid carcinoma
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Clinical experience with 18F-JK-PSMA-7 when using a digital PET/CT
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
Heterogeneous uptake of 18F-FDG and 18F-PSMA-1007 PET/CT in lung cancer and lymph node metastasis
PSMA-Liganden PET/CT bei Patienten mit biochemischem Rezidiv nach radikaler Prostatektomie: Matched-Pair Vergleich von 68Ga-PSMA-11 und 18F-PSMA-1007
Progressive Unilateral Proptosis and (18F) FDG-Avid Lesions Connoting Aggressive Disease in Radioiodine-Refractory Differentiated Thyroid Carcinoma